Das metabolische Syndrom - Mythen, Mechanismen, Management

M. Blüher; M. Stumvoll

doi:10.1055/s-2006-941745

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2006; 131(20): 1167-1172
DOI: 10.1055/s-2006-941745

Übersicht | Review article

Diabetologie, Endokrinologie, Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Das metabolische Syndrom - Mythen, Mechanismen, Management

Metabolic syndrome - myths, mechanisms, managementM. Blüher¹ , M. Stumvoll¹

¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Leipzig

Abstract

Schlüsselwörter

Metabolisches Syndrom - kardiovaskuläre Risikofaktoren - Diabetes mellitus - Hypertonie - Adipositas - Hyperlipidämie

Key words

syndrome X - metabolic syndrome - cardiovascular risk factors - diabetes mellitus - hypertension - obesity - hyperlipidaemia

Volltext

Referenzen

Literatur

1 Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15 539-553
2 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002; 105 310-315
3 Balkau B, Charles M A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16 442-443
4 Blüher M, Paschke R. Visceral adipose tissue and metabolic syndrome. Dtsch Med Wochenschr. 2003; 128 2319-2323
5 Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359 2072-2077
6 Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290 486-494
7 Colwell J A. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs. 2004; 4 87-106
8 DeFronzo R A, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14 173-194
9 Despres J P, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353 2121-2134
10 Dormandy J A, Charbonnel B, Eckland D J, Erdmann E, Massi-Benedetti M, Moules I K, Skene A M, Tan M H, Lefebvre P J, Murray G D, Standl E, Wilcox R G, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine R J, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366 1279-1289
11 Eckel R H, Grundy S M, Zimmet P Z. The metabolic syndrome. Lancet. 2005; 365 1415-1428
12 Einhorn D, Reaven G M, Cobin R H, Ford E, Ganda O P, Handelsman Y, Hellman R, Jellinger P S, Kendall D, Krauss R M, Neufeld N D, Petak S M, Rodbard H W, Seibel J A, Smith D A, Wilson P W. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003; 9 237-252
13 Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004; 92 1440-1446
14 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico M A, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987; 317 350-357
15 Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102 42-47
16 Gale E AM. The myth of the metabolic syndrome. Diabetologia. 2005; 48 1679-1683
17 Grundy S M, Cleeman J I, Daniels S R, Donato K A, Eckel R H, Franklin B A, Gordon D J, Krauss R M, Savage P J, Smith S C, Spertus J A, Costa F. American Heart Association; National Heart, Lung, and Blood Institute . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112 2735-2752
18 Hanefeld M, Leonhardt W. Das metabolische Syndrom. Dt Gesundheitswesen. 1981; 36 545-551
19 Hanefeld M, Scriba P. Metabolic syndrome. Internist. 1996; 37 679-680
20 Hanefeld M. Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract. 2002; 129 45-50
21 Hauner H. Insulin resistance and the metabolic syndrome - a challenge of the new millennium. Eur J Clin Nutr. 2002; 56 S25-29
22 Ibrahim H A, Vora J P. Hypertension in diabetes: a good opportunity to practise evidence-based medicine? A commentary on the UKPDS. United Kingdom Prospective Diabetes Study. J Hum Hypertens. 1999; 13 221-223
23 International Diabetes Federation .Worldwide definition of the metabolic syndrome. (www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf) 2005
24 Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24 683-689
25 Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes . The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28 2289-2304
26 King H, Aubert R E, Hermann W H. Global burden of diabetes, 1995 - 2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21 1414-1431
27 Klein S, Fontana L, Young V L, Coggan A R, Kilo C, Patterson B W, Mohammed B S. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004; 350 2549-2557
28 Kylien E. Studien Hypertonie - Hyperglykämie - Hyperurikämiesyndrome. Zentralblatt für Innere Medizin. 1923; 44 22-29
29 Lakka H M, Laaksonen D E, Lakka T A, Niskanen L K, Kumpusalo E, Tuomilehto J, Salonen J T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288 2709-2716
30 LaMonte M J, Barlow C E, Jurca R, Kampert J B, Church T S, Blair S N. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation. 2005; 112 505-512
31 Malik S, Wong N D, Franklin S S, Kamath T V, L’Italien G J, Pio J R, Williams G R. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110 1245-1250
32 McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003; 139 802-809
33 Meigs J B, D’Agostino R B, Wilson P W, Cupples L A, Nathan D M, Singer D E. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997; 46 1594-1600
34 Meigs J B, Mittleman M A, Nathan D M, Tofler G H, Singer D E, Murphy-Sheehy P M, Lipinska I, D’Agostino R B, Wilson P W. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000; 283 221-228
35 Meigs J B. Metabolic syndrome and risk for type 2 diabetes. Exp Rev Endocrinol Metab. 2006; 1 57-66
36 Orchard T J, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. Diabetes Prevention Program Research Group . The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142 611-619
37 Pearson T A, Blair S N, Daniels S R, Eckel R H, Fair J M, Fortmann S P, Franklin B A, Goldstein L B, Greenland P, Grundy S M, Hong Y, Miller N H, Lauer R M, Okkene I S, Sacco R L, Sallis J F, Smith S C, Stone N J, Taubert K A. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002; 106 388-391
38 Pischon T, Girman C J, Hotamisligil G S, Rifai N, Hu F B, Rimm E B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291 1730-1737
39 Pyorala K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997; 20 614-620
40 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37 1595-1607
41 Reaven G M. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 2005; 1 9-14
42 Rubins H B. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk. 2000; 7 339-345
43 Scheen A J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004; 30 487-496
44 Shen B J, Todaro J F, Niaura R, McCaffery J M, Zhang J, Spiro A, Ward K D. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol. 2003; 157 701-711
45 Smyth S, Heron A. Diabetes and obesity. The twin epidemics: Market Analysis. Nat Med. 2006; 12 75-80
46 Spranger J, Kroke A, Mohlig M, Bergmann M M, Ristow M, Boeing H, Pfeiffer A F. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361 226-228
47 Staiger H, Häring H U. Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diabetes. 2005; 113 67-79
48 Taylor A J, Sullenberger L E, Lee H J, Lee J K, Grace K A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; 110 3512-3517
49 Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnodt B, Stumvoll M, Claussen C, Fritsche A, Schick F, Haring H. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care. 2004; 27 2726-2729
50 The HOPE study investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355 253-259
51 Torgerson J S, Hauptman J, Boldrin M N, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27 155-161
52 Tuomilehto J, Lindstrom J, Eriksson J G, Valle T T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344 1343-1350
53 Vague J. The degree of masculine differentiation of obesities, a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr. 1956; 4 20-34
54 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. RIO-Europe Study Group . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365 1389-1397
55 Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005; 28 942-949
56 Wajchenberg B L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews. 2000; 21 697-738
57 Wilson P W, D’Agostino R B, Parise H, Sullivan L, Meigs J B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112 3066-3072

Prof. Dr. med. M. Stumvoll

Universität Leipzig, Medizinische Klinik und Poliklinik III

Philipp-Rosenthal-Straße 27

04103 Leipzig

Telefon: 0341/9713380

Fax: 0341/9713389

eMail: michael.stumvoll@medizin.uni-leipzig.de